Patients with lupus with COVID-19: University of Michigan experience
- PMID: 32475835
- PMCID: PMC12172630
- DOI: 10.1136/annrheumdis-2020-217794
Patients with lupus with COVID-19: University of Michigan experience
Keywords: arthritis, rheumatoid; hydroxychloroquine; lupus erythematosus, systemic.
Conflict of interest statement
Competing interests: JMK reports personal fees from AstraZeneca, personal fees from Eli Lilly, personal fees from Boehringer Ingleheim, and grants and personal fees from Bristol Myers Squibb, during the conduct of the study. No other authors have any competing interests to disclose.
Comment in
-
Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al.Ann Rheum Dis. 2021 Mar;80(3):e36. doi: 10.1136/annrheumdis-2020-217910. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475832 No abstract available.
Comment on
-
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24. Ann Rheum Dis. 2020. PMID: 32332072 No abstract available.
References
-
- Mathian A, Mahevas M, Rohmer J, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020;79:837–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical